Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ XFRA: 3XZ: Wiederaufnahme/Resumption (XETRA) +++ KAOKO METALS Aktie -7,02%

MYRIAD GENETICS Aktie

 >MYRIAD GENETICS Aktienkurs 
2.782 EUR    +1.4%    (TradegateBSX)
Ask: 2.781 EUR / 1790 Stück
Bid: 2.686 EUR / 1854 Stück
Tagesumsatz: 4 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
Aktie über LYNX handeln
>MYRIAD GENETICS Performance
1 Woche: +0,6%
1 Monat: -1,0%
3 Monate: -32,2%
6 Monate: -40,6%
1 Jahr: -51,9%
laufendes Jahr: -48,7%
>MYRIAD GENETICS Aktie
Name:  MYRIAD GENETICS DL-,01
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US62855J1043 / 897518
Symbol/ Ticker:  MYD (Frankfurt) / MYGN (NASDAQ)
Kürzel:  FRA:MYD, ETR:MYD, MYD:GR, NASDAQ:MYGN
Index:  -
Webseite:  https://myriad.com/
Profil:  Myriad Genetics Inc. is a molecular diagnostics and precision medicine company that develops genetic tests to support disease risk assessment, diagnosis, and treatment decisions. The company’s current portfolio spans oncology, women’s health, and..
>Volltext..
Marktkapitalisierung:  262.51 Mio. EUR
Unternehmenswert:  346 Mio. EUR
Umsatz:  696.15 Mio. EUR
EBITDA:  -35.73 Mio. EUR
Nettogewinn:  -97.18 Mio. EUR
Gewinn je Aktie:  -1.03 EUR
Schulden:  181.67 Mio. EUR
Liquide Mittel:  99.42 Mio. EUR
Operativer Cashflow:  6.65 Mio. EUR
Bargeldquote:  0.88
Umsatzwachstum:  -0.11%
Gewinnwachstum:  70.61%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel -
Suchwörter:  MYRIAD GENETICS
Letzte Datenerhebung:  07.09.26
>Kennzahlen
Aktien/ Unternehmen:
Aktien: 95.65 Mio. St.
Frei handelbar: 92.91%
Rückkaufquote: -1.12%
Mitarbeiter: 2700
Umsatz/Mitarb.: 0.26 Mio. EUR
Analysten:
Analystenrating: Neutral
Kursziel: 6.91%
Bewertung:
KGV: -
KGV lG: -
KUV: 0.37
KBV: 0.97
PEG-Ratio: -
EV/EBITDA: -
Rentabilität:
Bruttomarge: 65.1%
Gewinnmarge: -13.96%
Operative Marge: -11.22%
Managementeffizenz:
Gesamtkaprendite: -17.11%
Eigenkaprendite: -32.54%
>Peer Group
Gesundheit, Zell- & Gentherapie/ Gentechnik/ Erbkrankheiten, Psychische Erkrankungen/ Depressionen/ Schizophrenie, Kliniken, Pflegeheime & Gesundheitsdienstleistungen, Onkologie/ Krebs- Behandlung
 
01.09.26 - 19:48
Myriad Genetics downgraded at Piper Sandler on structural challenges (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
01.09.26 - 13:54
Piper Sandler stuft Myriad Genetics drastisch ab – Aktie bricht ein (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
10.08.26 - 16:09
Myriad Genetics (MYGN) Securities Investigation Notice - Levi & Korsinsky (PR Newswire)
 
Myriad Genetics reported Q2 2026 revenue of approximately $190.7 million against consensus of roughly $206-208 million, then cut full-year revenue guidance by about $90 million at the midpoint and suspended adjusted EBITDA guidance. Levi & Korsinsky is investigating potential securities......
04.08.26 - 16:09
MYGN SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Myriad Genetics (PR Newswire)
 
Myriad Genetics guided to adjusted gross margin of 68%-69% for 2026. Months later, the Company cut its revenue outlook, suspended EBITDA guidance, and MYGN shareholders absorbed the loss. NEW YORK, Aug. 4, 2026 /PRNewswire/ -- Myriad Genetics (NASDAQ: MYGN) investors are sitting on losses......
04.08.26 - 00:16
Myriad Genetics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Myriad Genetics (MYGN) (PR Newswire)
 
On May 5, 2026, Myriad Genetics management reaffirmed full-year revenue of $860-$880 million. Just three months later, the Company cut guidance to $770-$790 million and adjusted EBITDA guidance was suspended -- and MYGN shareholders absorbed the loss. NEW YORK, Aug. 3, 2026 /PRNewswire/......
31.07.26 - 01:45
Myriad Genetics (MYGN) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
 
Myriad (MYGN) delivered earnings and revenue surprises of -733.33% and -7.12%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?...
30.07.26 - 22:09
Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability (GlobeNewswire EN)
 
Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Scalability...
23.07.26 - 15:09
Myriad Genetics to Release Second Quarter 2026 Financial Results on July 30, 2026 (GlobeNewswire EN)
 
Myriad Genetics will hold its second quarter 2026 earnings conference call at 4:30 pm ET on Thursday, July 30, 2026....
21.07.26 - 15:09
Myriad Genetics Launches FirstGene® Multiple Prenatal Screen (GlobeNewswire EN)
 
Myriad Genetics Launches FirstGene® Multiple Prenatal Screen: The only lab test to run four prenatal genetic screens simultaneously as early as eight weeks...
17.07.26 - 18:00
AWHL vs. MYGN: Which Women′s Health Diagnostics Stock is Better Now? (Zacks)
 
Aspira and Myriad Genetics take different approaches to women's health diagnostics, but which stock looks more compelling now? Let's dive in....
23.06.26 - 15:09
Myriad Genetics Expands Availability of Precise MRD™ for Colorectal, Renal and Breast Cancers, Supported by New Publication (GlobeNewswire EN)
 
Publication of MONITOR-Breast study marks latest milestone for clinical validity of Precise MRD Publication of MONITOR-Breast study marks latest milestone for clinical validity of Precise MRD...
10.06.26 - 00:01
Insiderhandel: Aufsichtsrat verkauft Aktien von Myriad Genetics im Wert von 66843 USD (Insiderkauf)
 
Kumar, Rashmi - Aufsichtsrat - Tag der Transaktion: 2026-06-08...
09.06.26 - 17:30
Should You Add Myriad Genetics Stock to Your Portfolio Right Now? (Zacks)
 
MYGN is gearing up with oncology testing and steady product launches, backed by sound solvency, though foreign-exchange swings could weigh on results....
02.06.26 - 15:09
Myriad Genetics Names Raj Jampa as New Chief Technology Officer (GlobeNewswire EN)
 
Myriad Genetics announces the appointment of Raj Jampa as chief technology officer (CTO)....
28.05.26 - 16:45
Is MYGN Stock a Buy at 0.4x Sales? What Investors Should Weigh (Zacks)
 
Myriad Genetics trades near 0.4x sales as investors weigh cheap valuation against 2026 launch execution and uneven segment performance....
28.05.26 - 16:45
Myriad Genetics′ Upcoming Prolaris + AI Test Debut May Lift Its Stock (Zacks)
 
MYGN plans to launch its Prolaris + AI Test this month, combining biomarker data and AI pathology to personalize prostate cancer surveillance....
27.05.26 - 15:09
Myriad Genetics Highlights Data Showing Broad Clinical Utility of Precise MRD Assay at 2026 ASCO Annual Meeting (GlobeNewswire EN)
 
Myriad Genetics Highlights Data Showing Broad Clinical Utility of Precise MRD Assay at 2026 ASCO Annual Meeting...
26.05.26 - 22:09
Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI) (GlobeNewswire EN)
 
Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence...
15.05.26 - 17:03
Actress Jackie Tohn Got Results Nobody Wants But They May Have Saved Her Life (GlobeNewswire EN)
 
Myriad Genetics joins forces with Nobody Wants This actress Jackie Tohn...
15.05.26 - 02:02
Insiderhandel: Aufsichtsrat kauft Aktien von Myriad Genetics im Wert von 27638 USD (Insiderkauf)
 
Bisaro, Paul - Aufsichtsrat - Tag der Transaktion: 2026-05-14...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Ubi lex, ibi poena - Wo ein Gesetz, da auch eine Strafandrohung. - Nomen Nescio
>Aktienauflistung | >Aktienscreener | >Aktienkennzahlen | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!